FDA Issues New Warnings About Anti-Anemia Drugs
The US Food and Drug Administration has issued new warnings on several drugs commonly prescribed for cancer patients undergoing chemotherapy treatments.
The drugs, known as Erythropoiesis Stimulating Agents or ESAs, contain genetically engineered proteins used to increase red blood cell counts in many patients with cancer or chronic kidney failure.
The new warnings caution that ESA dosages administered when hemoglobin levels exceed 12 grams per deciliter have been linked to increased tumor growth and shortened survival in patients with advanced breast, head and neck, lymphoid, or non-small cell lung cancer. ESA dosing outside the range being recommended by the FDA has also been shown to increase the risk of stroke, heart attack, heart failure, and death in patients with chronic kidney failure.
ESAs are routinely dispensed to help patients combat the effects of acute anemia and avoid the risk and inconvenience of blood transfusions. The popular drugs are marketed under the brand names Aranesp®, Epogen® and Procrit®.
While the drugs are still approved for continued use, physicians are cautioned to evaluate each patient on a case-by-case basis to ensure ESA use is appropriate.
Source: washingtonpost.com
Related Links: Amgen (NASDAQ: AMGN); Ortho Biotech Products, LP; PharmaLive.com; Centers for Medicare and Medicaid Services; CNNMoney.com
Related Video: Alice on Anemia from Understanding Cancer TV
Tags: drug safety; oncology; darbepoetin alfa; epoetin alfa; pharmacology; prescription medications
Print This
|
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URI
Leave a comment
Browse All Categories: Next article: Improving the Informed Consent Process
Previous article: MMS May Help Men With Rare Penile Cancer

